Xbiotech Inc (XBIT)

Jan 17, 2025, 12:45 PM EST - 19 hours ago

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into XBiotech Inc. For Securities Fraud

Jan 17, 2025, 10:00 AM EST - 22 hours ago

Bronstein, Gewirtz & Grossman, LLC Encourages XBiotech Inc. (XBIT) Investors to Inquire about Securities Investigation

Jan 17, 2025, 5:19 AM EST - 1 day ago

XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm

Jan 16, 2025, 12:45 PM EST - 1 day ago

XBiotech Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Encouraged To Contact The Schall Law Firm

Jan 16, 2025, 10:00 AM EST - 1 day ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Investors to Reach Out

Jan 15, 2025, 11:15 AM EST - 2 days ago

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into XBiotech Inc For Securities Fraud

Jan 15, 2025, 10:00 AM EST - 2 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Stockholders to Reach Out

Jan 14, 2025, 4:37 PM EST - 3 days ago

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws

Jan 14, 2025, 11:15 AM EST - 3 days ago

XBiotech Inc. Is Being Investigated For Securities Law Violations And Impacted Investors Are Invited To Contact The Schall Law Firm

Jan 14, 2025, 11:15 AM EST - 3 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Stockholders to Connect

Jan 13, 2025, 9:15 PM EST - 4 days ago

The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Inquiry Into XBiotech Inc.

Dec 23, 2024, 9:00 AM EST - 25 days ago

XBiotech Pauses Rheumatology program

Jun 18, 2024, 1:08 PM EDT - 7 months ago

What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?

Jun 18, 2024, 11:35 AM EDT - 7 months ago

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

May 24, 2024, 4:08 PM EDT - 8 months ago

XBiotech: Several Shots On Goal In Big Target Market Indications

Jan 4, 2024, 9:00 AM EST - 1 year ago

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

Nov 14, 2023, 9:00 AM EST - 1 year ago

Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis

Sep 26, 2023, 9:00 AM EDT - 1 year ago

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

Aug 30, 2023, 9:00 AM EDT - 1 year ago

XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

Aug 8, 2023, 11:47 AM EDT - 1 year ago

XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial

May 22, 2023, 9:00 AM EDT - 1 year ago

FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients

May 17, 2023, 9:00 AM EDT - 1 year ago

XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares

Apr 17, 2023, 9:00 AM EDT - 1 year ago

XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

Oct 13, 2022, 12:46 PM EDT - 2 years ago

XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer

Jun 20, 2022, 9:00 AM EDT - 2 years ago

XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study

Apr 28, 2022, 2:56 PM EDT - 2 years ago

Why Are XBiotech Shares Trading Higher Today

Apr 28, 2022, 9:00 AM EDT - 2 years ago

XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer

Feb 2, 2022, 9:00 AM EST - 3 years ago

XBiotech Inks Clinical Manufacturing Deal

Jan 26, 2022, 9:50 AM EST - 3 years ago

XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ

Dec 13, 2021, 8:00 AM EST - 3 years ago

FDA Approves XBiotech's IND in Rheumatology

Oct 28, 2021, 11:59 AM EDT - 3 years ago

XBiotech to Launch Novel Candidate Therapy for Stroke

Jul 30, 2021, 11:03 AM EDT - 3 years ago

XBiotech Announces Payment of Dividend to Holders of Common Stock

Jul 6, 2021, 4:30 PM EDT - 3 years ago

XBiotech Announces Dividend to Holders of Common Stock

Jun 30, 2021, 11:46 AM EDT - 3 years ago

XBiotech Announces Receipt of $75 Million from Sale of Antibody

Jun 23, 2021, 8:30 AM EDT - 3 years ago

XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer

Apr 19, 2021, 7:08 AM EDT - 4 years ago

XBiotech To Test New Drug Candidate Combined With Approved Treatment In Pancreatic Cancer

Apr 19, 2021, 4:00 AM EDT - 4 years ago

FDA Gives Go-Ahead for XBiotech's Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer

Feb 26, 2021, 6:45 PM EST - 4 years ago

Top Small-Cap Stocks for March 2021

APPS CYH NARI NVAX RVP TBBK VERI